118
Participants
Start Date
October 31, 2012
Primary Completion Date
May 31, 2019
Study Completion Date
April 1, 2025
Cisplatin
administered intravenously every 3 weeks for 4 doses
Cyclophosphamide
administered with doxorubicin intravenously every 2 or 3 weeks for 4 doses
Doxorubicin
administered with Cyclophosphamide intravenously every 2 or 3 weeks for 4 doses
Georgetown University Medical Center, Washington D.C.
Johns Hopkins, Baltimore
Duke University, Durham
MD Anderson Cancer Center, Houston
University of Colorado Cancer Center, Aurora
Smilow Cancer Hospital Care Center at Derby, Derby
Smilow Cancer Hospital Care Center at Guilford, Guilford
St. Francis Hospital and Medical Center, Hartford
Yale School of Medicine, New Haven
Sibley Memorial Hospital, Washington D.C.
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Rutgers Cancer Institute of New Jersey, New Brunswick
Women and Infants Hospital, Providence
Dana-Farber Cancer Institute
OTHER
Beth Israel Deaconess Medical Center
OTHER